Abstract
Low survival rates in children with recurrent medulloblastoma (MB) necessitate the search for new therapeutic approaches as alternatives to the existing treatment standards. Favorable dosimetric characteristics of stereotactic radiation techniques justify the use of such treatments for local radiation control in children with oligometastatic recurrent MB. Given the constant risk of metastatic dissemination and in order to potentiate response to radiation therapy and improve progression-free survival, metronomic molecular-targeted antiangiogenic therapy (MEMMAT, Medulloblastoma European Multitarget Metronomic AntiAngiogenic Trial) can be considered in children with recurrent/progressive MB. Here, we report 2 clinical cases that demonstrate the effectiveness of the treatment approach involving stereotactic irradiation followed by the metronomic MEMMAT regimen for oligometastatic recurrent MB in pediatric patients. The patients’ parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
